MD Anderson at Cooper first in world to enroll patient in promising trial for metastatic melanoma
Source: Roi-Nj. Com, December 2023
Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte therapy.
Earlier this year, Camden-based MD Anderson at Cooper became the first site in the world to offer and enroll a patient in TILVANCE-301, a new randomized Phase III clinical trial evaluating the efficacy of “TIL” therapy as a first-line treatment versus pembrolizumab, the current standard of immunotherapy care, for advanced melanoma.
“TIL therapy is a promising, personalized approach to cancer treatment,” Dr. Young Ki Hong, surgical oncologist at MD Anderson at Cooper, and principal investigator of several TIL studies, said. “Our patient has had a remarkable response to this therapy. Each subsequent surveillance scan has shown a continuous reduction in the size of her tumor. We are grateful for patients who participate in clinical trials. Through their own treatment, they are helping to advance cancer care for others. As she completes her treatment, we are encouraged not only by her results, but what is means for patients in the future.”